A new way to kill aggressive prostate cancer with RB1 gene loss
Targeting Ferroptosis in Lethal RB1 Deficient Prostate Cancer
Researchers are trying to trigger a form of cell death called ferroptosis to kill aggressive prostate cancers that have lost the RB1 gene.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11301916 on NIH RePORTER |
What this research studies
In this project, scientists focus on men with metastatic castration‑resistant prostate cancer whose tumors have lost the RB1 gene. In laboratory models and animals they are testing drugs and drug combinations that induce ferroptosis, an iron‑dependent form of cell death, because RB1 loss seems to make cancer cells more vulnerable. Their work shows RB1 loss raises levels of ACSL4, a protein that increases ferroptosis sensitivity, and they are using that link to guide potential treatments. This is primarily preclinical research intended to identify therapies that could later be tested in patients with RB1‑deficient prostate cancer.
Who could benefit from this research
Good fit: Men with metastatic castration‑resistant prostate cancer whose tumors show RB1 loss or related biomarkers would be the most relevant candidates.
Not a fit: Patients whose tumors retain normal RB1 function or who have early‑stage disease are less likely to benefit from ferroptosis‑targeted approaches.
Why it matters
Potential benefit: If successful, this could lead to targeted therapies that selectively kill RB1‑deficient, treatment‑resistant prostate cancer cells.
How similar studies have performed: Early laboratory studies have shown ferroptosis can kill certain cancer cells, but translating this approach into effective patient treatments is still largely unproven.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Chen, Ming — Duke University
- Study coordinator: Chen, Ming
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.